

Strangvac (--)- Suspension for injection

Authorised

- Streptococcus equi subsp. equi, recombinant protein CCE
- Streptococcus equi subsp. equi, recombinant protein Eq85
- Streptococcus equi subsp. equi, recombinant protein IdeE

Product identification

Medicine name:

Strangvac (--)- Suspension for injection

Active substance:

Streptococcus equi subsp. equi, recombinant protein CCE
Streptococcus equi subsp. equi, recombinant protein Eq85
Streptococcus equi subsp. equi, recombinant protein IdeE

Target species:

Horse

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Streptococcus equi subsp. equi, recombinant protein CCE

Presentation_strength:≥111.8 µg Reference:Hse Index:0
Streptococcus equi subsp. equi, recombinant protein Eq85
Presentation_strength:≥44.6 µg Reference:Hse Index:1
Streptococcus equi subsp. equi, recombinant protein IdeE
Presentation_strength:≥34.6 µg Reference:Hse Index:2

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Horse

- Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI05AB01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Vial (glass), Package_size:8 vials, Content:2 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Intervacc AB

Marketing authorisation date:

16/08/2021

Manufacturing sites for batch release:

3P BIOPHARMACEUTICALS SL

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

16/08/2021

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 19/04/2024

[Download](#)

ema-puar-strangvac-epar-public-assessment-report-en.pdf